Advertisement

Landscape for Myeloproliferative Disorders Becoming More Defined With Improved Treatments, Biomarkers

Emerging therapies in myeloproliferative disorders such as polycythemia vera and myelofibrosis could have the potential to shake up the landscape. But, according to Michael J. Mauro, MD there is a great deal of work ahead for researchers.

 OncLive